27792644|t|Challenging Achievement of Bidirectional Block After Linear Ablation Affects the Rhythm Outcome in Patients With Persistent Atrial Fibrillation
27792644|a|It is not clear whether bidirectional block (BDB) of linear ablations reduces atrial fibrillation (AF) recurrence after radiofrequency catheter ablation. We hypothesized that BDB of linear ablation has prognostic significance after radiofrequency catheter ablation for persistent AF. Among 1793 consecutive patients in the Yonsei AF ablation cohort, this observational cohort study included 398 patients with persistent AF (75.6% male; age, 59.8±10.3 years) who underwent catheter ablation with a consistent ablation protocol of the Dallas lesion set: circumferential pulmonary vein isolation; cavotricuspid isthmus ablation (CTI); roof line (RL); posterior-inferior line (PIL); and anterior line (AL). BDB rates of de novo ablation lines were 100% in circumferential pulmonary vein isolation, 100% in CTI, 84.7% in RL, 44.7% in PIL, and 63.6% in AL. During 29.0±18.4 months of follow-up, 31.7% (126/398) of the patients showed clinical recurrence. Left atrial posterior wall (LAPW) isolation (BDBs of RL and PIL) was independently associated with lower clinical AF / atrial tachycardia recurrence (hazard ratio, 0.68; 95% CI, 0.47-0.98; P=0.041; log-rank, P=0.017), whereas BDBs of RL or AL were not (log-rank, P=0.178 for RL; P=0.764 for AL). Among 52 patients who underwent repeat procedures (23.0±16.1 months after de novo procedure), the BDB maintenance rates for CTI, RL, PIL, and AL were 94.2% (49 of 52), 63.5% (33 of 47), 62.1% (18 of 29), and 61.8% (21 of 34), respectively. Although PIL crosses the esophageal contact area, LAPW isolation is important for better clinical outcome in catheter ablation with a linear ablation strategy for patients with persistent AF.
27792644	0	23	Challenging Achievement	T033	C0474414
27792644	27	46	Bidirectional Block	T047	C0018794
27792644	53	68	Linear Ablation	T061	C0547070
27792644	81	95	Rhythm Outcome	T039	C1523018
27792644	99	107	Patients	T101	C0030705
27792644	113	143	Persistent Atrial Fibrillation	T046	C2585653
27792644	168	187	bidirectional block	T047	C0018794
27792644	189	192	BDB	T047	C0018794
27792644	197	213	linear ablations	T061	C0547070
27792644	214	221	reduces	T080	C0392756
27792644	222	241	atrial fibrillation	T047	C0004238
27792644	243	245	AF	T047	C0004238
27792644	264	296	radiofrequency catheter ablation	T061	C0162561
27792644	301	313	hypothesized	T062	C0681918
27792644	319	322	BDB	T047	C0018794
27792644	326	341	linear ablation	T061	C0547070
27792644	346	369	prognostic significance	T081	C0449821
27792644	376	408	radiofrequency catheter ablation	T061	C0162561
27792644	413	426	persistent AF	T046	C2585653
27792644	439	459	consecutive patients	T101	C0030705
27792644	467	492	Yonsei AF ablation cohort	T098	C0599755
27792644	499	525	observational cohort study	T081	C0009247
27792644	539	547	patients	T101	C0030705
27792644	553	566	persistent AF	T046	C2585653
27792644	574	578	male	T032	C0086582
27792644	580	583	age	T032	C0001779
27792644	595	600	years	T079	C0439234
27792644	616	633	catheter ablation	T061	C0162561
27792644	652	669	ablation protocol	T061	C0040808
27792644	677	694	Dallas lesion set	T170	C0025663
27792644	696	736	circumferential pulmonary vein isolation	T061	C3544330
27792644	738	768	cavotricuspid isthmus ablation	T061	C4087388
27792644	770	773	CTI	T061	C4087388
27792644	776	785	roof line	T061	C0162563
27792644	787	789	RL	T061	C0162563
27792644	792	815	posterior-inferior line	T061	C0162563
27792644	817	820	PIL	T061	C0162563
27792644	827	840	anterior line	T061	C0162563
27792644	842	844	AL	T061	C0162563
27792644	847	850	BDB	T047	C0018794
27792644	851	856	rates	T081	C1521828
27792644	868	882	ablation lines	T061	C0162563
27792644	896	936	circumferential pulmonary vein isolation	T061	C3544330
27792644	946	949	CTI	T061	C4087388
27792644	960	962	RL	T061	C0162563
27792644	973	976	PIL	T061	C0162563
27792644	991	993	AL	T061	C0162563
27792644	1012	1018	months	T079	C0439231
27792644	1022	1031	follow-up	T058	C1522577
27792644	1056	1064	patients	T101	C0030705
27792644	1072	1091	clinical recurrence	T067	C0034897
27792644	1093	1119	Left atrial posterior wall	T023	C0504042
27792644	1121	1125	LAPW	T023	C0504042
27792644	1127	1136	isolation	T061	C0204727
27792644	1138	1142	BDBs	T047	C0018794
27792644	1146	1148	RL	T061	C0162563
27792644	1153	1156	PIL	T061	C0162563
27792644	1176	1191	associated with	T080	C0332281
27792644	1192	1197	lower	T080	C0205251
27792644	1198	1209	clinical AF	T047	C0004238
27792644	1212	1230	atrial tachycardia	T046	C0546959
27792644	1243	1255	hazard ratio	T081	C2985465
27792644	1267	1269	CI	T081	C0009667
27792644	1291	1299	log-rank	T170	C0392366
27792644	1319	1323	BDBs	T047	C0018794
27792644	1327	1329	RL	T061	C0162563
27792644	1333	1335	AL	T061	C0162563
27792644	1368	1370	RL	T061	C0162563
27792644	1384	1386	AL	T061	C0162563
27792644	1398	1406	patients	T101	C0030705
27792644	1421	1438	repeat procedures	T058	C0520262
27792644	1450	1456	months	T079	C0439231
27792644	1463	1480	de novo procedure	T059	C0022885
27792644	1487	1490	BDB	T047	C0018794
27792644	1503	1508	rates	T081	C1521828
27792644	1513	1516	CTI	T061	C4087388
27792644	1518	1520	RL	T061	C0162563
27792644	1522	1525	PIL	T061	C0162563
27792644	1531	1533	AL	T061	C0162563
27792644	1638	1641	PIL	T061	C0162563
27792644	1654	1677	esophageal contact area	T023	C0014876
27792644	1679	1683	LAPW	T023	C0504042
27792644	1684	1693	isolation	T061	C0204727
27792644	1711	1734	better clinical outcome	T033	C1333602
27792644	1738	1755	catheter ablation	T061	C0162561
27792644	1763	1787	linear ablation strategy	T061	C0547070
27792644	1792	1800	patients	T101	C0030705
27792644	1806	1819	persistent AF	T046	C2585653